Loading…
The role of intestinal microbiota is significant in the development of ulcerative colitis (UC). It is proposed that prebiotics may enhance health by modifying the composition and/or activity of gut microbiota (1)
A triple-blinded, randomized treatment trial (Single Group Assignment) to evaluate Fructooligosaccharides (FOS) + Inulin-type fructans (ITF) / Inulin (7.5 g/day dose vs 15 g/day dose) in 25 patients with mild/moderately active Ulcerative colitis (UC) (1)
Number of patients who show a decrease in the Mayo score ≥ 3 but the total Mayo score remains ≥ 3.
Fructans had a significant impact on reducing colitis in the high-dose group, with 77% of patients experiencing a clinical response compared to 33% in the low-dose group (P = 0.04). Additionally, fructans increased colonic butyrate production at a dose of 15 g/d, and fecal butyrate levels showed a negative correlation with the Mayo score (r = −0.50; P = 0.036) (1)
The pilot study demonstrated that administering a 15 grams per day dose of inulin-type fructans in individuals with ulcerative colitis (UC) led to functional changes in the gut microbiota, rather than compositional ones. This suggests that the metabolic alterations induced by prebiotics in the gut microbiota are more crucial for the benefits observed in UC than changes in composition. These findings highlight the need for future well-powered controlled studies to explore the use of β-fructans as an adjunct therapy for patients with active UC (1)
(1)